Prosecution Insights
Last updated: April 19, 2026
Application No. 18/048,652

GUIDEWIRE GUIDE CONFIGURATIONS FOR IMPLANTABLE MEDICAL DEVICES

Non-Final OA §102
Filed
Oct 21, 2022
Examiner
PATEL, NIDHI NIRAJ
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Tc1 LLC
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
3y 10m
To Grant
99%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allow Rate
61 granted / 109 resolved
-14.0% vs TC avg
Strong +46% interview lift
Without
With
+45.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
39 currently pending
Career history
148
Total Applications
across all art units

Statute-Specific Performance

§101
16.3%
-23.7% vs TC avg
§103
43.7%
+3.7% vs TC avg
§102
15.7%
-24.3% vs TC avg
§112
19.3%
-20.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group II (Claims 9-14) in the reply filed on November 24, 2025 is acknowledged. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 9-14 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Keenan (US 20130303970 A1). With respect to claim 9, Keenan discloses A catheter assembly for use in a percutaneous heart pump (see paragraph 0024, percutaneous catheter pump), the catheter assembly comprising: an impeller assembly (see Fig. 2, impeller assembly #92; and see Fig. 7A-7B) comprising: an impeller (see Figs. 3A-3B and paragraph 0028-0030, impeller #300; and see Figs. 7A-7B and paragraph 0061-0068, impeller #703); an impeller tip positioned distal of the impeller (see Figs. 3A-3B and paragraph 0028-0030, impeller tip is the most distal end of #300; and see Figs. 7A-7B and paragraph 0061-0068, #709); and a distal septum positioned between the impeller and the impeller tip (see paragraph 0012, a re-sealable member interpreted to be a septum can be disposed distally of impeller; and see Figs. 7A-7B and paragraph 0061-0068, re-sealable member or a septum #754); a flexible atraumatic tip (FAT) positioned distal of the impeller assembly (see Fig. 3A, atraumatic tip is positioned distal of impeller assembly and as seen in Fig. 3A it is curved at the end); and a guidewire guide (GWG) coupled between the impeller assembly and the flexible atraumatic tip (see Figs. 7A-7B and paragraph 0061-0068, a guidewire guide tube #750 can pass through impeller shaft and is coupled between the tip and impeller assembly), wherein a proximal end of the guidewire guide is positioned distal of the distal septum (see Figs. 7A-7B and paragraph 0061-0068). With respect to claim 10, all limitations of claim 9 apply in which Keenan further discloses wherein the GWG is flexible and resilient (see paragraph 0060, the guidewire guide tube may be disposed through a central lumen of the catheter pump to the heart; and see paragraph 0064, guidewire guide is stainless steel and has high durometer polymer used to re-seal it) to facilitate (a) reducing kinking as the catheter assembly is delivered to a left ventricle of a patient’s heart and (b) maintaining a rigid length of the catheter assembly (intended use; the guidewire guide tube is capable of facilitating reduced kinking and maintaining rigid length of catheter assembly). With respect to claim 11, all limitations of claim 9 apply in which Keenan further discloses wherein the GWG is constructed from flexible alloys including at least one of nitinol, a grade of stainless steel (see paragraph 0064, guidewire guide is stainless steel) , or advanced polymers such as polyamide, HDPE, LLDPE, FEP, PET, Pebax, etc. With respect to claim 12, all limitations of claim 9 apply in which Keenan further discloses wherein the distal septum is pierceable when a guidewire passes through the GWG prior to a procedure (see Figs. 7A-7B and paragraph 0061-0068, a guidewire guide tube #750 can pass through impeller shaft and a guidewire passes through the tube and pierces the re-sealable member #754). With respect to claim 13, all limitations of claim 9 apply in which Keenan further discloses wherein the distal septum is configured to seal after a guidewire is removed (see Figs. 7A-7B and paragraph 0061-0068, re-sealable member #754 can be employed to reseal the aperture formed with the guidewire or guidewire guide is removed). With respect to claim 14, all limitations of claim 9 apply in which Keenan further discloses an expandable cannula (see paragraph 0012, catheter pump includes an expandable cannula). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIDHI PATEL whose telephone number is (571)272-2379. The examiner can normally be reached Mondays to Fridays 9AM-5PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Robertson can be reached at (571) 272-5001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /N.N.P./Examiner, Art Unit 3791 /ERIC J MESSERSMITH/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Oct 21, 2022
Application Filed
Jan 03, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12551666
GUIDEWIRE WITH CORE CENTERING MECHANISM
2y 5m to grant Granted Feb 17, 2026
Patent 12527524
BED-BASED BALLISTOCARDIOGRAM APPARATUS AND METHOD
2y 5m to grant Granted Jan 20, 2026
Patent 12527503
CANNULA INSERTION SYSTEM
2y 5m to grant Granted Jan 20, 2026
Patent 12521049
BIOLOGICAL FLUID SEPARATION DEVICE
2y 5m to grant Granted Jan 13, 2026
Patent 12514485
AN APPARATUS AND METHOD FOR ASSESSING BALANCE
2y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
99%
With Interview (+45.9%)
3y 10m
Median Time to Grant
Low
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month